A new wave of scrutiny has followed the Sunday announcement of President Joe Biden’s prostate cancer diagnosis—an aggressive, late-stage form with a Gleason score of 9, denoting both high malignancy and confirmed metastasis to the bones. The controversy gained traction after NewsNation aired an interview with urologist Dr. David Shusterman, who cast doubt on the official timeline presented by the White House.
In a video circulating widely online Dr. Shusterman questioned the plausibility of such an advanced cancer being diagnosed only recently, citing both the nature of the disease and the rigorous medical protocols typically afforded to a sitting president. “The idea that this could have been missed, especially with the kind of medical attention a president receives, is surprising,” Shusterman said. He emphasized that prostate-specific antigen (PSA) levels, a routine metric in standard screenings, would have signaled trouble long before the cancer advanced to the point of bone metastasis.
Urologist Dr. David Shusterman says there's no way Biden and his doctors didn't know about this aggressive prostate cancer much earlier.pic.twitter.com/I92sKUGEhV
— Citizen Free Press (@CitizenFreePres) May 19, 2025
The Gleason scoring system grades prostate cancer cells based on how abnormal they appear under a microscope. A score of 9 (out of 10) indicates a highly aggressive, poorly differentiated cancer—one that grows rapidly and is prone to spreading. This classification often demands intensive treatment and carries a guarded prognosis. Given the score and metastasis, Dr. Shusterman suggested that Biden’s condition likely developed over the course of several years, not months—making the recent disclosure all the more suspect.
Shusterman also addressed the potential cognitive side effects of standard therapies for advanced prostate cancer, particularly androgen-deprivation therapy (ADT). Drugs like Lupron, a common ADT agent, are known to cause a range of side effects including fatigue, mood changes, and cognitive decline. While he stopped short of making a direct claim, Shusterman raised the possibility that such treatments—if administered earlier—could have impacted Biden’s cognitive performance during his presidency.
The revelation of Biden’s prostate cancer diagnosis has not only raised questions about the timing and transparency of health disclosures but also intersected with another significant political event: the release of the Biden-Hur tapes. These tapes, from October 2023 interviews with Special Counsel Robert Hur, have provided a stark audio record of Biden’s cognitive struggles, including memory lapses and difficulty recalling key details about his own life and tenure. The tapes, which surfaced just days before the cancer announcement, have intensified scrutiny over Biden’s fitness for office and the management of his health by his administration.
🚨NEW — Partial audio of the Robert Hur interview with then-President Joe Biden has just been released.
It's BRUTAL.
He clearly had no idea what was going on — or when things had happened.
This was a scandal — The Democrats & the media covered it up. pic.twitter.com/d7m8co3M1w
— Townhall.com (@townhallcom) May 16, 2025
Critics argue that the simultaneous emergence of these issues suggests a pattern of delayed or obscured information, further eroding public trust. As the nation grapples with these developments, the convergence of Biden’s health challenges and the Hur tapes underscores a critical moment of reflection on leadership, accountability, and the demands of transparency in the highest office.
[Read More: Mexican Pirate Ship Runs Into Brooklyn Bridge]
How long did Biden have cancer
Why didnt the WH MD Team spot it
Was this from VP years
During race for WH?
Why the Cover Up Jill